Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Ghidini

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
Cancer Immunology, Immunotherapy : CII|August 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuationMarco Russano, Alessio Cortellini, Raffaele Giusti, et al.
British Journal of Cancer|May 28, 2024
The road to tailored adjuvant chemotherapy for all four non-pancreatic periampullary cancers: An international multimethod cohort studyBas A Uijterwijk, Daniël H Lemmers, Michele Ghidini, et al.
Annals of Surgical Oncology|June 18, 2024
The Five Periampullary Cancers, not Just Different Siblings but Different Families: An International Multicenter Cohort StudyBas A Uijterwijk, Daniël H Lemmers, Michele Ghidini, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
Journal of the National Cancer Institute|April 12, 2023
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort studyLuca Cantini, Francesco Paoloni, Federica Pecci, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
United European Gastroenterology Journal|July 29, 2025
The Brescia International Multidisciplinary Consensus Guidelines on the Optimal Pathology Assessment and Multidisciplinary Pathways of Non-Pancreatic Neoplasms in and Around the Ampulla of Vater (PERIPAN)Mohammad Abu Hilal, Bas A Uijterwijk, Daniël H L Lemmers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with CancerAlessio Cortellini, Antonio D'Alessio, Siobhan Cleary, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
Cancer Immunology, Immunotherapy : CII|August 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuationMarco Russano, Alessio Cortellini, Raffaele Giusti, et al.
British Journal of Cancer|May 28, 2024
The road to tailored adjuvant chemotherapy for all four non-pancreatic periampullary cancers: An international multimethod cohort studyBas A Uijterwijk, Daniël H Lemmers, Michele Ghidini, et al.
Annals of Surgical Oncology|June 18, 2024
The Five Periampullary Cancers, not Just Different Siblings but Different Families: An International Multicenter Cohort StudyBas A Uijterwijk, Daniël H Lemmers, Michele Ghidini, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
Journal of the National Cancer Institute|April 12, 2023
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort studyLuca Cantini, Francesco Paoloni, Federica Pecci, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
United European Gastroenterology Journal|July 29, 2025
The Brescia International Multidisciplinary Consensus Guidelines on the Optimal Pathology Assessment and Multidisciplinary Pathways of Non-Pancreatic Neoplasms in and Around the Ampulla of Vater (PERIPAN)Mohammad Abu Hilal, Bas A Uijterwijk, Daniël H L Lemmers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with CancerAlessio Cortellini, Antonio D'Alessio, Siobhan Cleary, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Pageof 21